Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
During the past 13 years, the highest Dividend Payout Ratio of Rekah Pharmaceutical Prod was 3.26. The lowest was 3.26. And the median was 3.26.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
During the past 13 years, the highest Dividend Yield of Rekah Pharmaceutical Prod was 5.74%. The lowest was 0.00%. And the median was 4.79%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod Dividends per Share Related Terms
Rekah Pharmaceutical Prod Dividends per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod Dividends per Share Chart
XTAE:REKA vs ZTS, UTHR, VTRS: Dividends per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's Dividend Yield % falls into.
Rekah Pharmaceutical Prod (XTAE:REKA) has a Dividends per Share of ₪0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Rekah Pharmaceutical Prod and its competitors.
Is Rekah Pharmaceutical Prod's Dividends per Share too high?
Rekah Pharmaceutical Prod's current Dividends per Share is ₪0.00. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Dividends per Share compare to ZTS and UTHR?
Rekah Pharmaceutical Prod's Dividends per Share of ₪0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Rekah Pharmaceutical Prod and its competitors. Rekah Pharmaceutical Prod's current Dividends per Share is ₪0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.06, compared to a current price of ₪11.00 — trading 15.8% below its estimated fair value. The current Dividends per Share is ₪0.00. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Dividends per Share is ₪0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪11.00 is trading 15.8% below its estimated GF Value™ of ₪13.06.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
Dividends per Share: ₪0.00
GF Value™: ₪13.06 vs. price of ₪11.00 (15.8% below fair value)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
